HOME >> BIOLOGY >> NEWS
Researchers discover new mechanism that targets and destroys abnormal RNA

c diseases in which mutations cause premature termination of protein production.

A specific example is the testing of drugs called aminoglycosides to treat cystic fibrosis and other diseases caused by premature termination codons, said Dietz. The idea is that these drugs would allow read-through of such codons, to generate adequate levels of full-length functional proteins. Unfortunately, these drugs have not performed very well, he said.

Our studies of the effects of one such drug on yeast indicate that this read-through generates mRNAs that trigger the nonstop decay mechanism to degrade them, said Dietz. This finding offers the promise that drugs that inhibit nonstop decay might enable aminoglycoside drugs to function as effective treatments for some genetic diseases.

Termination codons are present in about one-third of human disease genes, representing literally thousands of genes, said Dietz. So this dual-drug treatment strategy could be relevant to a large number of human disorders, including cystic fibrosis and muscular dystrophy.

In the second Science paper, lead author Ambro van Hoof, in Parkers laboratory, did experiments that revealed the specific cellular machinery that produces nonstop decay. According to Parker, those experiments showed that a multi-enzyme complex called the exosome is important for nonstop decay.

The exosome is a collection of enzymes called exonucleases that snip apart RNA molecules. In their experiments, van Hoof, Parker and their colleagues set out to see if the exosome was involved in nonstop mRNA decay.

It was known that the exosome was involved in a variety of RNA degradation processes in the cell, probably controlled through specific adapters, although we really dont understand the mechanisms well, said Parker. According to Parker, the adapter protein, which is attached to the exosome, somehow recognizes the nonstop RNA and attaches to the ribosome.

Parker, van Hoof
'"/>

Contact: Jim Keeley
keeleyj@hhmi.org
301-215-8858
Howard Hughes Medical Institute
21-Mar-2002


Page: 1 2 3 4

Related biology news :

1. Researchers determine genetic cause of Timothy syndrome
2. Researchers find color sensitive atomic switch in bacteria
3. Researchers identify protein promoting vascular tumor growth
4. Researchers devise potent new tools to curb ivory poaching
5. Researchers create nanotubes that change colors, form nanocarpet and kill bacteria
6. Researchers ID chlorophyll-regulating gene
7. Researchers develop fast track way to discover how cells are regulated
8. Researchers identify distinctive signature for metastatic prostate cancer
9. Researchers report new gene test for isolated cleft lip and palate
10. Researchers discover why mutant gene causes colon cancer
11. Researchers identify the genomes controlling elements

Post Your Comments:
(Date:8/21/2014)... , Aug. 21, 2014 /PRNewswire-iReach/ -- ... it has agreed to a partnership with Gabriel ... fastest growing Certified Nursing Assistant ... Health Institute  an exclusive member of Binary,s LiveScan ... Binary Biometrics will improve its service capabilities ...
(Date:8/21/2014)... In a finding that has implications for life in ... in the solar system, LSU Associate Professor of Biological ... National Science Foundation, or NSF, this week published a ... lake that lies 800 meters (2600 feet) beneath the ... microbial ecosystems.", Given that more than 400 subglacial lakes ...
(Date:8/21/2014)... Oct. 18-22, 2014 , WHERE: , San ... Diego, CA 92101 , WHAT: , Invited ... the latest research in human genetics. Examples of ... abstracts on rare genetic variants in health and ... for sun sensitivity (Saturday, Oct. 18, 5:30-7:30 pm) ...
Breaking Biology News(10 mins):LiveScan Provider Binary Biometrics Announces Partnership with Preeminent CNA School, Gabriel Health Institute to Expand Services in Orlando Region 2LiveScan Provider Binary Biometrics Announces Partnership with Preeminent CNA School, Gabriel Health Institute to Expand Services in Orlando Region 3800 meters beneath Antarctic ice sheet, subglacial lake holds viable microbial ecosystems 2800 meters beneath Antarctic ice sheet, subglacial lake holds viable microbial ecosystems 3800 meters beneath Antarctic ice sheet, subglacial lake holds viable microbial ecosystems 4American Society of Human Genetics 2014 Annual Meeting 2
(Date:8/21/2014)... (PRWEB) August 21, 2014 Pursuit ... selling optimization technology and services for Life Sciences ... “Grading Pharma’s Use of New Commercial Sales Models” ... & Analytics. , The article examines some innovative ... that are being tested in the pharmaceutical market. ...
(Date:8/21/2014)... August 21, 2014 Gallus ... contract development and manufacturing organization (CMO) announced today ... Inc., an oncology company focused on the development ... to manufacture the anti-prostate specific membrane antigen (PSMA) ... candidate. Under the agreement the antibody will ...
(Date:8/21/2014)... of last week RENU 28, the world's first and only ... purchase in Australia and New Zealand, and the response has ... if you think about the definition of aging, it's really ... your body. If you think about the definition of anti-aging, ... RENU 28 does is it works with these tiny little ...
(Date:8/20/2014)... inventions licensed to biotechnology firms has revealed early ... these roadblocks, the researchers suggest that better communication ... could lead to faster commercialization down the road. ... made in university laboratories and licensed to biotechnology ... which have a high failure rate. But a ...
Breaking Biology Technology:Pursuit's Peter Robinson Publishes "Grading Pharma's Use of New Commercial Sales Models" 2Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 2Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 3RENU 28 Skin Care Now Available in Australia and New Zealand 2Early bottlenecks in developing biopharmaceutical products delay commercialization 2Early bottlenecks in developing biopharmaceutical products delay commercialization 3
Cached News: